Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Cipla Lines Up Foreign Governments For Its Tamiflu Generic

This article was originally published in PharmAsia News

Executive Summary

Cipla of India says it has reached an agreement to sell its generic version of Roche's Tamiflu (oseltamivir) to Mexico to treat the A/H1N1 flu virus. The World Health Organization has declared Cipla's Antiflu as effective as Roche's branded product. Cipla's head, Yusuf Hamled, said the company also is negotiating similar arrangements with several other countries in Africa, Latin America and the Middle East. Roche and Tamiflu's patent holder, Gilead, recently lost an Indian court case against the Cipla generic. (Click here for more

You may also be interested in...



India May Ban Open Sale Of Cipla's Generic Zanamavir

MUMBAI - Cheaper copies of GlaxoSmithKline's anti-flu drug Relenza (zanamavir) being marketed by Cipla under its own brand name, Virenza, may be banned from retail sale in the Indian market as a measure of precaution to prevent building resistance to the H1N1 virus, unscrupulous hoarding and stockpiling

Industry Delighted By ‘Fixed’ USMCA

Industry associations in the US and Canada have welcomed revisions to the proposed US-Mexico-Canada trade agreement that remove potentially damaging provisions around biologic data exclusivity and include measures favorable to generics, including incentives for generic competition.

NeuClone’s Trastuzumab Trial Succeeds

NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.

UsernamePublicRestriction

Register

SC071626

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel